Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 805 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Inequalities cause 2,000 extra cancer cases in Wales June 8, 2023 Olivia Newton-John Talks About Her Use Of Medical Cannabis During Cancer... May 28, 2019 How radiotherapy became a lifesaver – from X-rays to the proton... July 8, 2022 Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... November 7, 2023 Load more HOT NEWS “My Heart Will Always Hurt”: How I Honor My Childhood Best... FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations 5-Year-Old Boy Meets Generous Stem Cell Donor Who Cured Him
